Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

Shunya Ikeda, Yukari Yamada, Naoki Ikegami

Research output: Contribution to journalArticle

44 Citations (Scopus)


To demonstrate the economic impact of donepezil treatment for patients with mild to moderate Alzheimer's disease (AD) in Japanese clinical settings, we conducted a cost-utility analysis using the Markov model. This analysis was made from a payer's perspective, and the cost was estimated based on the fee schedule of the Japanese national health insurance and the long-term care insurance. The results of the clinical trial of donepezil on AD in Japan were used to estimate the drug efficacy. Under the base-case analysis with a 2-year time horizon, donepezil treatment for patients with mild to moderate AD was considered to be an economically dominant strategy compared to conventional therapy.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalDementia and Geriatric Cognitive Disorders
Issue number1
Publication statusPublished - 2002 Jan 1



  • Alzheimer's disease
  • Donepezil
  • Economic evaluation, Cost-utility analysis
  • Quality-adjusted life years

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Cognitive Neuroscience
  • Psychiatry and Mental health

Cite this